Preoperative Herceptin and Navelbine for Breast Cancer
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects the preoperative combination therapy of
herceptin and navelbine have on HER-2 positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital